A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe COvid-19 (PISCO) trial protocol
一项平行组、多中心、随机、双盲、安慰剂对照的 II/III 期临床试验，旨在检验低剂量溴吡斯的明降低重症 SARS-CoV-2 感染成人患者死亡率或有创机械通气需求的疗效：重症 COVID-19 患者溴吡斯的明 (PISCO) 试验方案
期刊:BMC Infectious Diseases
影响因子:3
doi:10.1186/s12879-020-05485-7
Fragoso-Saavedra, Sergio; Iruegas-Nunez, David A; Quintero-Villegas, Alejandro; García-González, H Benjamín; Nuñez, Isaac; Carbajal-Morelos, Sergio L; Audelo-Cruz, Belem M; Arias-Martínez, Sarahi; Caro-Vega, Yanink; Calva, Juan José; Luqueño-Martínez, Verónica; González-Duarte, Alejandra; Crabtree-Ramírez, Brenda; Crispín, José C; Sierra-Madero, Juan; Belaunzarán-Zamudio, Pablo F; Valdés-Ferrer, Sergio I
